Remove Big Data Remove Genome Remove Protein
article thumbnail

Breaking Barriers in Solid Tumor Research: Precision Medicine & Strategic Operations

Worldwide Clinical Trials

Advanced technologies like artificial intelligence for analyzing big data, patient genetic registries, and liquid biopsies enhance patient identification and monitoring while reducing participant burden and expediting study timelines.

Medicine 100
article thumbnail

The future of AI drug discovery & development in immunology and GPCR research

pharmaphorum

A mere six months ago Verily launched the study with Sosei Heptares – a global leader in GPCR structure-based drug design – with an aim to “prioritise protein targets for therapeutic targeting in immune-mediated disease”. Verily’s Immune Profiler can, Kim asserted, “generate more than 8 million immune measures across 24 immune cell subsets”.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Integrated evidence generation 2.0: A strategy for every stakeholder

pharmaphorum

The advent of biologic therapies in the 1970s along with the decoding of the human genome in 2003 heralded an explosion in pharmaceutical innovation.

article thumbnail

A history of AstraZeneca

pharmaphorum

The same year, AZ also entered into its third collaboration agreement with Astex Therapeutics, this time to develop small-molecule protein kinase B (PKB) to further contribute in the fight against cancer. AstraZeneca’s first acquisition following its creation was of KuDOS Pharmaceuticals, a UK biotech company, for £120 million in 2005.